SUPPLEMENTARY TABLE S2. Demographic and baseline characteristic data (modified intent-to-treat population)

|  | Mesalamine dose groups | |
| --- | --- | --- |
| Parameter | Low dose  (n = 41) | High dose  (n = 41) |
| Age, median (range), years | 14 (6–17) | 13 (5–17) |
| Age categories, n (%) |  |  |
| 5–8 years | 4 (9.8) | 4 (9.8) |
| 9–17 years | 37 (90.2 | 37 (90.2) |
| Sex, n (%) |  |  |
| Female | 22 (53.7) | 23 (56.1) |
| Male | 19 (46.3) | 18 (43.9) |
| Race, n (%) |  |  |
| Black | 2 (4.9) | 2 (4.9) |
| White | 37 (90.2) | 39 (95.1) |
| Multiracial | 2 (4.9) | 0 |
| Bodyweight, median (range), kg | 52.8 (23.0–88.9) | 49.8 (17.1–85.4) |
| Height, median (range), cm | 160.9 (118–182) | 160.3 (110–191) |
| Bodyweight categories, n (%) |  |  |
| 17 to <33 kg | 5 (12.2) | 7 (17.1) |
| 33 to <54 kg | 17 (41.5) | 17 (41.5) |
| 54–90 kg | 19 (46.3) | 17 (41.5) |
| Disease severity, n (%) |  |  |
| Mild | 21 (51.2) | 18 (43.9) |
| Moderate | 20 (48.8) | 23 (56.1) |
| Time since original diagnosis, median (range), months | 1.1 (0.1–101.6) | 2.2 (0–151.9) |
| Extent of ulcerative colitis |  |  |
| Missing | 8 (19.5) | 5 (12.2) |
| Proctitis | 3 (7.3) | 5 (12.2) |
| Proctosigmoiditis | 7 (17.1) | 4 (9.8) |
| Left-sided colitis | 10 (24.4) | 6 (14.6) |
| Extensive colitis | 3 (7.3) | 4 (9.8) |
| Pancolitis | 10 (24.4) | 17 (41.5) |
| Relapse frequency |  |  |
| Relapse more than once a month | 3 (7.3) | 2 (4.9) |
| Relapse once every 6 months | 3 (7.3) | 3 (7.3) |
| Relapse once every 6–12 months | 4 (9.8) | 6 (14.6) |
| Relapse less than once a year | 5 (12.2) | 5 (12.2) |
| Relapse less than every 18 months | 1 (2.4) | 2 (4.9) |
| Newly diagnosed | 25 (61.0) | 23 (56.1) |
| Duration of current attack, median (range), months | 2.2 (0.3–18.3) | 2.4 (0.3–11.1) |
| Previous (prior to randomization) exposure to oral mesalamine | 18 (43.9) | 16 (39) |
| Total PUCAI score, median (range) | 30 (15–50) | 35 (15–55) |

PUCAI = Pediatric Ulcerative Colitis Activity Index.